The Synthesis and Evaluation of Flavone and Isoflavone Chimeras of Novobiocin and Derrubone
| dc.contributor.author | Mays, Jared R. | |
| dc.contributor.author | Hill, Stephanie A. | |
| dc.contributor.author | Moyers, Justin T. | |
| dc.contributor.author | Blagg, Brian S. J. | |
| dc.date.accessioned | 2017-05-04T20:00:49Z | |
| dc.date.available | 2017-05-04T20:00:49Z | |
| dc.date.issued | 2010-01-01 | |
| dc.identifier.citation | Mays, J. R., Hill, S. A., Moyers, J. T., & Blagg, B. S. J. (2010). The Synthesis and Evaluation of Flavone and Isoflavone Chimeras of Novobiocin and Derrubone. Bioorganic & Medicinal Chemistry, 18(1), 249. http://doi.org/10.1016/j.bmc.2009.10.061 | en_US |
| dc.identifier.uri | http://hdl.handle.net/1808/23899 | |
| dc.description.abstract | The natural products novobiocin and derrubone have both demonstrated Hsp90 inhibition and structure–activity relationships have been established for each scaffold. Given these compounds share several key structural features, we hypothesized that incorporation of elements from each could provide insight to structural features important for Hsp90 inhibition. Thus, chimeric analogues of novobiocin and derrubone were constructed and evaluated. These studies confirmed that the functionality present at the 3-position of the isoflavone plays a critical role in determining Hsp90 inhibition and suggests that the bicyclic ring system present in both novobiocin and derrubone do not share similar modes of binding. | en_US |
| dc.publisher | Elsevier | en_US |
| dc.rights | This article is made available under an Attribution-NonCommercial-NoDerivs 3.0 United States (CC BY-NC-ND 3.0 US) License. | en_US |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/3.0/us/ | en_US |
| dc.subject | Hsp90 | en_US |
| dc.subject | Novobiocin | en_US |
| dc.subject | Derrubone | en_US |
| dc.subject | Anticancer | en_US |
| dc.title | The Synthesis and Evaluation of Flavone and Isoflavone Chimeras of Novobiocin and Derrubone | en_US |
| dc.type | Article | en_US |
| kusw.kuauthor | Mays, Jared R. | |
| kusw.kuauthor | Hill, Stephanie A. | |
| kusw.kuauthor | Moyers, Justin T. | |
| kusw.kuauthor | Blagg, Brian S. J. | |
| kusw.kudepartment | Medicinal Chemistry | en_US |
| kusw.oanotes | Per SherpaRomeo on 05/04/2017: Author's Pre-print: green tick author can archive pre-print (ie pre-refereeing) Author's Post-print: green tick author can archive post-print (ie final draft post-refereeing) Publisher's Version/PDF: cross author cannot archive publisher's version/PDF General Conditions: Authors pre-print on any website, including arXiv and RePEC Author's post-print on author's personal website immediately Author's post-print on open access repository after an embargo period of between 12 months and 48 months Permitted deposit due to Funding Body, Institutional and Governmental policy or mandate, may be required to comply with embargo periods of 12 months to 48 months Author's post-print may be used to update arXiv and RepEC Publisher's version/PDF cannot be used Must link to publisher version with DOI Author's post-print must be released with a Creative Commons Attribution Non-Commercial No Derivatives License | en_US |
| dc.identifier.doi | 10.1016/j.bmc.2009.10.061 | en_US |
| kusw.oaversion | Scholarly/refereed, author accepted manuscript | en_US |
| kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
| dc.identifier.pmid | PMC2818389 | en_US |
| dc.rights.accessrights | openAccess |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as: This article is made available under an Attribution-NonCommercial-NoDerivs 3.0 United States (CC BY-NC-ND 3.0 US) License.
